Skip to main content

Table 4 Comparison of rheumatoid arthritis patient characteristics between patients with/without incidental metabolic syndrome

From: Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity

Characteristics

MetS-free patients

Patients with incidental MetS

P value

( n= 74)

( n= 39)

Socio-demographic

   

Female gender

68 (91.9)

35 (89.7)

0.74

Age (years)

33.6 ± 11.9

42.7 ± 13.8

0.000

Years of formal education

11.6 ± 3.6

10 ± 4.2

0.04

Current smokers

10 (13.5)

2 (5.1)

0.21

Females with menopause (142 female)

4 (4.4)

7 (20)

0.03

BMI (kg/m2)

23.9 (21.5 to 26.6)

26.8 (24.5 to 29.8)

0.000

Disease characteristics

   

Disease duration (months)

5.4 (3.9 to 7)

5.3 (2.9 to 7.3)

0.38

Patients with RF

59 (79.7)

29 (74.4)

0.63

Patients with ACCP

63 (85.1)

29 (74.4)

0.21

Cumulativea DAS28

2.4 (2.1 to 3.05)

3.3 (2.7 to 5.8)

0.000

Cumulativea ESR (mm/hour)

12.5 (8.6 to 18.2)

21 (10.2 to 35)

0.008

Cumulativea CRP (mg/dl)

0.28 (0.15 to 0.58)

0.52 (0.26 to 1.21)

0.007

Cumulativea HAQ

0.2 (0.12 to 0.43)

0.38 (0.25 to 1.13)

0.001

Patients with erosions at index datea

27 (34.5)

23 (59)

0.03

Follow-up (months)

72 (42 to 94.5)

90 (70 to 108)

0.003

Comorbid conditions

   

Patients with ≥1 comorbid condition

35 (47.3)

20 (51.3)

0.67

Patients with diabetes

0

1 (2.6)

0.35

Patients with hypertension

1 (1.4)

3 (7.7)

0.12

Patients with BMI ≥30 kg/m2

3 (4.1)

10 (25.6)

0.001

Treatment at baseline

   

Patients with DMARDs

15 (32.6)

15 (38.5)

0.12

Patients with corticosteroids

26 (35.1)

12 (30.8)

0.68

Patients with antimalarials

12 (16.2)

8 (20.5)

0.61

Patients with other drugs

37 (50)

22 (56.4)

0.56

  1. Data presented as n (%), mean ± standard deviation or median (range). ACCP, antibodies to cyclic citrullinated peptides; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score evaluated in 28 joints; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome; RF, rheumatoid factor. aConsidered up to MetS diagnosis in patients with incidental MetS and up to last follow-up in the patients without incidental MetS.